La chaîne d'options affiche les données clés des options sur actions de Petros Pharma à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Petros Pharma..

Petros Pharma (NASDAQ:PTPI) Stock, Chaîne d'Options

Petros Pharmaceuticals

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharmaceuticals Inc

PT CHANDRA ASRI PACIFIC by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

UBS analyst Dennis Geiger maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Neutral and lowers the price target from $16 to $14.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on Wendy's, Lowers Price Target to $14

Waste Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) reported mixed first-quarter financial results after the bell on Monday, and shares are moving lower. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/b45054510/wm-announces-first-quarter-2025-earnings">of the report</a>.
<ul>
<li>Q1 Revenue: $6.02 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $6.12 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: $1.67, versus estimates of $1.62</li>
</ul>
Total revenue was up 16.7% on a year-over-year basis. Waste Management said it generated $1.21 billion in cash from operations during the quarter, resulting in $475 million in free cash flow, in line with company expectations.
The company ended the first quarter with $216 million in cash and cash equivalents, down from $414 million at the end of the fourth quarter. 
&#8220;These solid&nbsp;first quarter&nbsp;results, as well as the strength and resiliency of our business model, give us confidence we are on pace to achieve our 2025&nbsp;outlook,&#8221; said&nbsp;Jim Fish, president and CEO of Waste Management.
Waste Management <a href="https://www.benzinga.com/pressreleases/25/01/b43324253/wm-announces-fourth-quarter-and-full-year-2024-earnings">previously guided</a> for full-year revenue of $25.5 billion to $25.8 billion. The company also forecasted for full-year free cash flow of approximately $2.68 billion to $2.78 billion when it reported fourth-quarter results.
Waste Management executives will further discuss the quarter on a conference call with investors and analysts at 10 a.m. ET Tuesday morning.
WM Price Action: <a href="http://benzinga.com/quote/WM">Waste Management shares</a> were down 1.78% at $225.01 after-hours at publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">NXP Semiconductors Reports Q1 Earnings: &#8216;Very Uncertain&#8217; Operating Environment Tied To Tariffs, CEO Transition, Shares Fall</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45054717/transocean-stock-climbs-after-mixed-q1-results-eps-miss-revenue-beats">Transocean Stock Climbs After Mixed Q1 Results: EPS Miss, Revenue Beats</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45053893/amkor-technology-shares-climb-after-q1-revenue-beats-q2-revenue-guidance-above-estimates">Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/paulmatthew">BCFC</a>/Shutterstock.

Earnings

After-Hours Center

Movers

Waste Management Stock Dips On Mixed Q1 Results, Company Says It's 'On Pace' To Achieve 2025 Outlook

UBS analyst Dennis Geiger maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Neutral and lowers the price target from $300 to $255.

WING

UBS Maintains Neutral on Wingstop, Lowers Price Target to $255

UBS analyst Timothy Arcuri maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and lowers the price target from $130 to $92.

UBS Maintains Buy on Micron Technology, Lowers Price Target to $92

UBS analyst Spiro Dounis maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Buy and lowers the price target from $144 to $140.

UBS Maintains Buy on Phillips 66, Lowers Price Target to $140

NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) sees Q2 sales of $2.171 billion-$2.238 billion vs $2.18 billion analyst estimate.

Guidance

NOV Sees Q2 Sales $2.171B-$2.238B vs $2.18B Est

UBS analyst Thomas Wadewitz maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $422 to $305.

SAIA

UBS Maintains Buy on Saia, Lowers Price Target to $305

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.25 per share. This is a 7.41 percent decrease over earnings of $0.27 per share from the same period last year. The company reported $33.55 million in sales this quarter. This is a 4.99 percent decrease over sales of $35.31 million the same period last year.

National Research Q1 EPS $0.25 Down From $0.27 YoY, Revenue $33.55M Down From $35.31M YoY

NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.26 by 26.92 percent. This is a 36.67 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $2.10 billion which met the analyst consensus estimate. This is a 2.41 percent decrease over sales of $2.15 billion the same period last year.

Earnings Misses

NOV Q1 EPS $0.19 Misses $0.26 Estimate, Sales $2.10B Inline

UBS analyst Dennis Geiger maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Neutral and lowers the price target from $105 to $90.

SBUX

UBS Maintains Neutral on Starbucks, Lowers Price Target to $90

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 15.4% on an annualized basis producing an average annual return of 29.66%. Currently, Krystal Biotech has a market capitalization of $4.89 billion. 
Buying $100 In KRYS: If an investor had bought $100 of KRYS stock 5 years ago, it would be worth $359.67 today based on a price of $169.73 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745876711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

KRYS

Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

UBS analyst Lloyd Walmsley maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Buy and lowers the price target from $5960 to $5557.

BKNG

UBS Maintains Buy on Booking Holdings, Lowers Price Target to $5557

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is looking for Q2 GAAP EPS of $0.35-$0.48 vs $0.51 analyst estimate..

Teradyne Sees Q2 GAAP EPS $0.35-$0.48 vs $0.51 Est

UBS analyst Jay Sole maintains Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) with a Neutral and lowers the price target from $37 to $32.

UBS Maintains Neutral on Carter's, Lowers Price Target to $32

<a href="https://www.bloomberg.com/news/articles/2025-04-28/boeing-removed-from-credit-watch-by-s-p-in-turnaround-boost?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-04-28/boeing-removed-from-credit-watch-by-s-p-in-turnaround-boost?embedded-checkout=true</a>

General

'Boeing Removed From Credit Watch by S&P in Turnaround Boost'- Bloomberg

UBS analyst Stephen Ju maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and lowers the price target from $194 to $170.

EXPE

UBS Maintains Neutral on Expedia Group, Lowers Price Target to $170

German American Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GABC#NASDAQ">GABC</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.66 by 19.7 percent. This is a 27.42 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $81.41 million which beat the analyst consensus estimate of $79.56 million by 2.33 percent. This is a 33.87 percent increase over sales of $60.82 million the same period last year.

Earnings Beats

GABC

German American Bancorp Q1 Adj. EPS $0.79 Beats $0.66 Estimate, Sales $81.41M Beat $79.56M Estimate

UBS analyst Brian Meredith maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Buy and lowers the price target from $145 to $140.

GSHD

UBS Maintains Buy on Goosehead Insurance, Lowers Price Target to $140

UBS analyst Ashwani Verma maintains Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and lowers the price target from $55 to $48.

HRMY

UBS Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $48

Linkbancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKB#NASDAQ">LNKB</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.24 by 16.67 percent. This is a 25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $39.09 million which beat the analyst consensus estimate of $32.48 million by 20.34 percent. This is a 46.88 percent increase over sales of $26.61 million the same period last year.

LNKB

Linkbancorp Q1 Adj. EPS $0.20 Misses $0.24 Estimate, Sales $39.09M Beat $32.48M Estimate

Biotech

Events

Press Releases

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Comments

Petros Pharma

Petros Pharma (PTPI) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL